Special Focus: Molecular and Cellular Events Controlling Neuronal and Brain Function and Dysfunction

Neuronal protein trafficking associated with Alzheimer disease

From APP and BACE1 to glutamate receptors

Bor Luen Tang

Department of Biochemistry; Yong Loo Lin School of Medicine; National University of Singapore; Singapore, Singapore

Key words: amyloid precursor protein (APP), β-site APP cleaving enzyme 1 (BACE1), endosome, glutamate receptors, trans-Golgi network (TGN)

Aberrant and/or cumulative amyloid-beta (Aβ) production, resulting from proteolytic processing of the amyloid precursor protein (APP) by β and γ-secretases, have been postulated to be a main etiological basis of Alzheimer disease (AD). A number of proteins influence the subcellular trafficking itinerary of APP and the β-site APP-cleaving enzyme (BACE1) between the cell surface, endosomes and the trans-Golgi network (TGN). Available evidence suggests that co-residence of APP and BACE1 in the endosomal compartments promotes amyloidogenesis. Retrograde transport of APP out of the endosome to the TGN reduces Aβ production, while APP routed to and kept at the cell surface enhances its non-amyloidogenic, α-secretase-mediated processing. Changes in post-Golgi membrane trafficking in aging neurons that may influence APP processing is particularly relevant to late-onset, idiopathic AD. Dystrophic axons are key features of AD pathology, and impaired axonal transport could play crucial roles in the pathogenesis of idiopathic AD. Recent evidence has also indicated that Aβ-induced synaptic defects and memory impairment could be explained by a loss of both AMPA and NMDA receptors through endocytosis. Detail understanding of factors that influence these neuronal trafficking processes will open up novel therapeutic avenues for preventing or delaying the onset of symptomatic AD.

The Amyloid Cascade Hypothesis of Alzheimer Disease

An estimate 24.3 million people in the world have dementia in 2005.1 With an extrapolated 4.6 million new cases of dementia every year, the number of dementia patient will double every 20 years, reaching 81.1 million by 2040. The neurodegenerative disease first reported by Alois Alzheimer2 a hundred years ago3,4 is the most common course of dementia in the elderly above 65 years. Alzheimer disease (AD), as it has become known, is therefore the neurodegenerative disease that has attracted the most research focus in the past decades.

Over 95% of AD cases are late-onset, sporadic and have a complex, idiopathic etiology. A small number of early-onset AD cases has hereditary monogenic defects, and investigations on the underlying mutations had provided important clues for understanding AD pathology. AD presents two distinct pathological features—intracellular neurofibrillary tangles (NFTs) and extracellular amyloid plaques. Both features have clear connections to neuronal demise and consequential onset of dementia symptoms. NFTs comprise of bundles of filaments twisted about each other in pairs (known as paired helical filament, PHF), and contain abnormally hyperphosphorylated forms of the microtubule-binding protein tau.5 Amyloid plaques are made up of insoluble aggregates of amyloid β (Aβ) peptides.6,7 NFTs and amyloid plaques are functionally related, and the latter could potentially promote tau hyperphosphorylation and NFT pathogenesis.8,9

The amyloid cascade hypothesis10 posits that accumulation of Aβ peptide, generated from proteolytic cleavages of the amyloid precursor protein (APP) in the brain, is the source of extracellular plaques, and the primary etiological agent of AD. However, extracellular amyloid plaque burden does not necessarily correlate with clinical AD symptoms, and it is known that Aβ exists in multiple assembly states, with each exhibiting different physiological or pathophysiological effects.11-13 Accumulating evidence also suggests that both intracellular and extracellular soluble oligomeric forms of Aβ are capable of inducing synaptic defects and the onset of AD symptoms.14-17

As summarized in Figure 1, Aβ is generated from APP (but not its paralogues APLP1 and APLP2) by a sequential two-step proteolytic process involving β- and γ-secretases.18,19 APP is first cleaved by the β-site APP cleaving enzyme 1 (BACE1),20,21 a member of the pepsin family of aspartyl proteases, to generate a membrane bound C-terminal fragment (C99, CTβ). A subsequent γ-secretase activity further generates peptides mainly of 40 or 42 amino acids in length, termed Aβ40 and Aβ42, as well as the remaining APP intracellular domain (AICD). Minor forms of Aβ peptides, including Aβ35, Aβ37, Aβ38 and others with less clear neuropathological roles, can also be generated. Aβ40 is more abundant than Aβ42 and although both could be found in amyloid plaques, Aβ42 is apparently more
directly neurotoxic, and has a greater propensity to oligomerize and to form fibrils. Interestingly, Aβ40 appears to be able to reverse the above effect and properties of Aβ42. Alternative APP proteolytic processing pathways exist, most notably by α-secretases of the A Disintegrin and Metalloprotease (ADAM) family of surface metalloproteases. α-secretase cleavage occurs at a site that effectively abolishes BACE1 recognition. The α-secretase cleaved C-terminal fragment (CTFα) is also subsequently cleaved by γ-secretase. However, the small fragment generated as such, named p3, is non-amyloidogenic and has no recognized role in AD. α-secretase cleavage also generates a soluble sAPPα fragment that has some neuroprotective properties.

The γ-secretase responsible for Aβ generation upon β-secretase-mediated cleavage of APP is not a single polypeptide. Rather, the proteolytic activity resides in a complex which mediates a unique process of regulated intramembrane proteolysis (RIP) of several proteins, such as APP, Notch, and cadherin. The active complex consists of at least four proteins—presenilins (PS)-1 or -2 at the catalytic core, nicastrin, anterior pharynx-defective phenotype 1 (APH1, two isoforms—APH1a and APH1b) and PS-enhancer 2 (PEN-2). A fifth component, p23/TMP21, a member of the p24 cargo protein family, has recently been identified as part of the γ-secretase complex. As alluded to above, γ-secretase cleavage also generates the AICD fragment, with possible transcriptional functions. Other than cleavages by the conventional α, β- and γ-secretase, the intracellular domain of APP is also processed by caspases to a small 31-amino acid fragment that was shown to induce apoptosis. APP is also cleaved by the mitochondrial serine protease HtrA2, generating a C161 fragment (encompassing amino acids 535–695 of APP695), which function is yet unclear.

Known genetic predispositions to early-onset AD are primarily associated with mutations in APP and the presenilins 1/2 component of the γ-secretase complex. All these mutations increase somewhat the generation of Aβ, or the Aβ42/Aβ40 ratio. Endowment with the apolipoprotein E (ApoE) ε4 allele is a known risk factor for late-onset AD. ApoE ε4 appears to influence Aβ physiology in the aging brain in terms of its oligomerization and clearance, perhaps through its roles in lipid and cholesterol homeostasis. On that note, there is evidence for high cholesterol levels in mid-life being a risk for AD and preliminary evidence have suggested that cholesterol-lowering statins could reduce this risk. The low density lipoprotein receptor (LDLR) family of proteins, which binds ApoE, modulates APP trafficking and proteolytic processing (see section 3 below). The neuronal sortilin related receptor 1 (SorL1, also named LR11 or SorLA) has in fact been recently found to be genetically associated with late-onset AD. Several other potential genetic links to AD are known, including components of all three classes of the APP secretases, but not robustly confirmed. Excellent web information resources for these potential AD genes and loci could be found at www.alzforum.org.

APP interacts with multiple proteins, and these myriad of interacting partners could influence APP processing and AD pathology. Several diverse groups of molecules which superficially appear unrelated to AD pathology have also recently been shown to influence Aβ levels in vitro and in vivo through interactions with APP or the secretases. These include the reticulon family members, the Nogo-66 receptor, the Rho family GTPases and their effectors, as well as the peptidyl-prolyl isomerase Pin1. Another important and interesting aspect of AD pathology concerns metals. Metal ions such as zinc and copper can interact with both APP and Aβ to potentiate AD by enhancing their aggregation as well as the generation of reactive oxygen species. Oxidative stress has indeed been proposed to be a major mechanism for chronic neuronal death in AD.
Neuronal membrane protein traffic, regulated or deregulated, plays vital roles in AD pathology. Although the etiology of AD appears complex, the pathological roots could be traced to Aβ generation from APP. APP and BACE1 have rather similar subcellular trafficking patterns and itineraries. Effective meeting and reaction between enzyme and substrate as they traverse the cell surface, endosome/lysosome, the trans-Golgi network (TGN) and the early secretory pathway would therefore determine the extent of Aβ production. Emerging evidence suggests that colocalization and interaction between APP and BACE1 in the endosomal compartments promotes amyloidogenesis. Retrograde transport of APP out of the endosome to the TGN reduces Aβ production, while APP routed to and kept at the cell surface enhances its non-amyloidogenic, α-secretase-mediated processing. Changes in post-Golgi membrane trafficking in aging neurons that may influence APP processing are therefore particularly relevant to late-onset, sporadic AD. Recent evidence also indicates that Aβ induced synaptic defects and memory impairment could be explained by loss of both the ionotropic glutamate receptors (AMPA and NMDA receptors) through localized dendritic spine endocytosis, involving fundamental mechanisms that are responsible for synaptic plasticity. This chapter focuses on how membrane traffic processes (and their defects thereof) may influence APP processing and Aβ production, as well as how Aβ could in turn cause synaptic defects by influencing the homeostatic trafficking of glutamate receptors.

Membrane Traffic Itinerary and Localization of APP, BACE1 and γ-secretase—Sites of APP Cleavage and Aβ Production

Both APP and BACE1 are type I membrane proteins with rather similar membrane traffic itineraries. Made at the cell body, they traverse both the exocytic and endocytic pathways of intracellular membrane traffic, and assume at least transient residence in various membrane compartments (summarized in Fig. 2). Productive interaction between APP and BACE1 resulting in β-secretase cleavage could potentially occur at multiple points in the ER, TGN, cell surface, endosome and lysosomes.72,73 The γ-secretase complex, on the other hand, has a different mode of biogenesis (which includes functional subunit assembly) and membrane traffic dynamics from APP/BACE1. Identifying the predominant site (or sites) of β- and γ-secretase cleavages and consequential Aβ production has been controversial. The issues have been complicated by cell line and methodological differences, and the fact that localization or cleavage site may be altered as a result of mutations in the components concerned. Experimental overexpression of one component may also affect the trafficking of another. For example, high BACE1 expression could shift the subcellular location of APP cleavage to more proximal parts of the secretory pathway.74

β-secretase cleavage sites. β-secretase cleavage is the critical first step in amyloidogenic APP processing, and brain Aβ load correlated well with increased β-secretase activity in sporadic AD patients.75,76 As BACE1 knockout mice appeared healthy,86 BACE1 has emerged as a primed therapeutic target for AD.77-79 Understanding BACE1 trafficking in relation to APP and Aβ production is therefore important. Early studies have indicated that Aβ production involves the endocytic pathway,80 and recent studies have strengthened the notion that endosomes are the principle sites of β-cleavage.81 APP has at least two putative endocytic signaling motifs at its cytoplasmic tail, and detail analysis by scanning mutagenesis indicated that the tetrapeptide sequence of YENP is the dominant signal for APP internalization.82 Upregulation of the endocytic pathway stimulated by the endosomal Rab5 increased Aβ production,83 while inhibition of dynamin-dependent endocytosis reduced it.84

The β-secretase activity has been known for some time, and the particularly tricky problem of investigating an enzyme activity without an identity was eventually resolved with the cloning of BACE1.20 Mature BACE1 is found on the cell surface and endosomes, but not ER or lysosomes.85 Sensitive fluorescence microscopy analysis by fluorescence resonance energy transfer (FRET) indicated that APP and BACE1 interact at the cell surface and endosomes, but not lysosomes.86 Since biochemical studies indicate that BACE1 has an acidic pH optimum,87 it follows that the acidic endosomes are the main compartments in which β-cleavage of APP occurs. This notion is further supported by the fact that cellular factors which influence APP and BACE1’s trafficking in and out of endosomes also modulate Aβ production (see section 3 below).

γ-secretase cleavage sites. Attempts to identify the main γ-secretase cleavage site(s) have generated a good deal of controversy. Inhibition of γ-cleavage resulting from presenilin (PS)-1 knockout88 and subsequent demonstration that it contains the catalytic site,89 established it as an essential component of the γ-secretase activity. Unlike APP and BACE1, however, both PS1 and PS2 were localized to compartments of the early secretory pathway (ER and Golgi),90 and there is evidence for “active” γ-secretase activity in a pre-Golgi compartment.91 The exact localization of γ-secretase activity is also undoubtedly complicated by the fact that we are looking at a multi-protein complex that needs to be assembled92,93 and also by the fact that active presenilin is itself an endoproteolyzed, membrane bound polypeptide. γ-secretase activity have been demonstrated in multiple cellular locations, even in the mitochondria.94 More recent analysis is consistent with functional γ-secretase activity concentrating on the cell surface and in early endosomes.95

A potential function of presenilin that has not received as much attention as its catalytic activity is its role in protein trafficking.96 In particular that of APP?97 Surface APP transport is defective in cells overexpressing PS1 mutants which cause familial AD.97 PS1 interacts with phospholipase D1 (PLD1).98 Overexpression of PLD1 in wild type cells promotes generation of APP-containing vesicles from the TGN, corrects impaired neurite outgrowth in PS1 mutant neurons, and reduced Aβ production.99 Presenilin/γ-secretase activity is also apparently required for normal endosomal recycling of soluble and membrane-associated proteins, and treatment with γ-secretase inhibitors resulted in the accumulation of APP and APP-CTFs in the recycling endosome.100

Where is Aβ produced in the neurons? β cleavage versus α cleavage. Many cell types in the body express APP. In the brain, BACE1 expression is observed in most neurons. Glia cells expressed little or undetectable BACE1 under normal conditions, although activated astrocytes may have elevated BACE1 expression.20,101 Neurons are therefore believed to be the major source of Aβ produced in the brain. Mature neurons are highly polarized cells with distinct axonal and somatodendritic plasma membrane domains. Endosomal compartments can be found in both axons and dendrite in isolation from those at the cell body. The dendrite is also endowed
Neuronal protein trafficking associated with Alzheimer disease

with rather elaborate internal membranes of the ER and Golgi.\textsuperscript{102} In view of the highly polarized and complex traffic processes that occur in a neuron, it would be of considerable interest to know if there is a main site of Aβ generation, especially in connection with excess generation during AD pathology.

Another point of interest stems from the fact that proteolytic processing of APP by \( \alpha \)-secretases would essentially preclude \( \beta \)-cleavage and Aβ generation\textsuperscript{103} and Aβ generation is therefore influenced by APP’s close encounters with either secretases in its trafficking itinerary. The plasma membrane was shown to be the major site for \( \alpha \)-secretase cleavage of APP.\textsuperscript{104,105} In polarized Madin-Darby canine kidney (MDCK) cells, APP is predominantly targeted to the basolateral membrane where \( \alpha \)-secretases are found, but BACE1 is instead targeted to the apical membrane.\textsuperscript{106,107} APP processing in MDCK cells therefore occurs mainly by \( \alpha \)-cleavage.\textsuperscript{107} In hippocampal neurons, BACE1 is mainly targeted to the axons\textsuperscript{107} (analogous to the epithelial apical domain). On the other hand, APP has been shown in early studies to undergo axonal transport,\textsuperscript{108} but could be transcytosed to dendrites.\textsuperscript{109} Recent work also suggests that APP can be transported in a non-signal dependent manner to both axons and dendrites.\textsuperscript{110} It appears that APP could be processed by both BACE1 and \( \alpha \)-secretase on axonal plasma membranes. However, keeping in mind that BACE1 has an acidic pH optimum and is most active in endosomes, it would logically follow that axonal presynaptic endosomes may be a major site of Aβ production. This notion is supported by findings that endoproteolytic fragments of PS1 can be found in synaptic organelles and growth cone membranes,\textsuperscript{111} but requires further experimental confirmation. In any case, it should be intuitively clear from the discussions above that the time spent by APP in the endosome versus that of other compartments (such as TGN and the plasma membrane) could have a major influence on Aβ production. Alterations in APP processing in favor of \( \beta \)-secretase cleavage resulting from changes in its trafficking dynamics and resident time in the endosomes, perhaps due to neuronal aging and cumulative oxidative damage, could therefore be relevant for late-onset, sporadic AD. This notion is explored further below as we look at how APP traffic and Aβ production is influenced by multiple cellular factors.

Figure 2. Trafficking itinerary of APP and BACE1. A schematic diagram of the trafficking itinerary of APP and BACE1. Both proteins have very similar itinerary and can be found in compartments of the exocytic pathway and endocytic pathway. Locations of general components of membrane traffic known to affect APP/BACE1 traffic, such as gamma-ear-containing ARF-binding (GGA) proteins and the retromer complex are also shown. Although presenilins are largely localized to the ER-Golgi region at steady state, these and other components of the \( \gamma \)-secretase complex also have widespread presence. Note that this is a general scheme which does not include detailed depiction of neuronal domains such as axons and dendrites. Dark arrows indicate exocytic or anterograde transport and white arrow endocytic or retrograde trafficking. ER, endoplasmic reticulum; ERGIC, ER-Golgi intermediate compartment; TGN, trans-Golgi network; EE, early endosome; RE, recycling endosome; LE, late endosome; L, lysosome.
**Factors Participating in or Influencing APP/BACE1/γ-Secretase Traffic and Aβ Production**

A myriad of cellular factors and processes are known to influence APP/BACE1/γ-secretase traffic and consequential Aβ production. These include general molecular components of exocytic and endocytic traffic, as well as cargo adaptors that may specifically associate with APP. Their mode of function and interactions are briefly summarized below.

**General protein trafficking components in APP/BACE1/γ-secretase traffic.** Vesicular transport of APP and BACE1 is governed by the basic molecular machinery of protein traffic in eukaryotic cells. Both molecules are transported in their post-Golgi routes by clathrin-coated vesicles through its associated adaptor proteins. Polarized transport of APP in epithelial cells is mediated by the adaptor protein complex AP1-1B, and a similar complex likely interacts with APP in neurons. APP, particularly the cytoplasmic NPXY motif, is known to interact with a host of molecules with implicated functions as cargo adaptors. Some of these molecules also interact with and regulate the trafficking of the ApoE receptor 2 (ApoER2). These are considered collectively in the following section. We first look at two known coat adaptor complexes that mediate BACE1 and APP traffic.

The cytoplasmic domain of BACE1 contains an acid cluster dileucine motif that binds the Vps-27, Hrs and STAM (VHS) domain of Golgi-localized gamma-ear-containing ARF-binding (GGA) proteins. Overexpression of GGA1 in cells was reported to increase the level of APP C-terminal fragment (CTFβ) resulting from β cleavage but paradoxically reduced Aβ levels, which suggest that GGA1 somehow prevents CTFβ from being subjected to subsequent γ-secretase cleavage.

Another report, which showed that GGA1 is enriched in neurons of human brain, demonstrated that overexpression of GGA1, or a dominant-negative variant, reduced CTFβ generation and Aβ secretion. On the other hand, silencing of GGA1 increased Aβ secretion. The general picture provided by these reports showed that GGA have a pivotal influence on the cellular trafficking of BACE1 (and APP) between the TGN and the endosomal compartments, which in turn affects Aβ biogenesis. How GGA-mediated processes may change during AD pathology is still unclear. Interestingly, BACE1 levels appear to be regulated by that of GGA3. GGA3 protein levels were significantly decreased in AD brains, and this inversely correlated with increased levels of BACE1.

Another coat complex implicated in the transport of BACE1 is the retromer complex, which has an evolutionarily conserved function in endosome-to-Golgi transport. Retromer components are highly expressed in the brain, and silencing of the retromer component VPS26 incurred a change in BACE1 trafficking that was similar to GGA silencing. Both VPS26 and VPS35 levels are reduced in brain regions selectively vulnerable to AD. Like the GGAs, the retromer complex likely modulates BACE1 and APP partitioning between the endosome and the TGN. Although a role for the retromer complex in AD pathology is not supported by the lack of an association between its genetic polymorphism and AD risk, changes in retromer subunit levels with age could contribute to late onset AD.

Other than coat proteins, the other two major classes of components of the mammalian protein traffic machinery, namely the Rab and SNAREs, are less implicated in the modulation of APP or BACE1 traffic. Rab1B and Rab6, which regulates transport at the ER-Golgi boundary and the Golgi-TGN, respectively, appeared to influence APP processing. One would also expect SNAP (soluble NSF attachment protein) and NSF (N-ethylmaleimide-sensitive factor) attachment receptors (SNAREs) operating at the TGN and endosomes of neurons to participate in APP and BACE1 trafficking. Changes in the function and activities of these SNAREs should influence Aβ biogenesis, but have not yet been reported as such.

**APP-interacting adaptor proteins influence APP trafficking and Aβ generation.** Tyrosine phosphorylation of the YENPTY sorting motif at APP’s C-terminus resulted in its interaction with several cystolic phosphotyrosine binding (PTB) domain or Src homology 2 (SH2) domain-containing proteins. Some of these, such as the munc-18 interacting proteins (Mints)/X11s, mammalian Disabled (DAB), the Fe65 family of proteins and the JNK-interacting proteins (JIPs), have been extensively implicated in the modulation of APP trafficking and Aβ production. Almost invariably, these adaptors also influence trafficking of the ApoE receptor, ApoER2. It was recently shown that binding of ApoE to ApoER2 triggers the endocytosis of APP, BACE1, and ApoER2 in neuroblastoma cells, thereby increasing the production of Aβ. This is apparently mediated by X11α or X11β, which bind both APP and the cystolic domain of ApoER2. Another report showed that X11γ/Mint3 and APP are found in the same purified transport vesicles. Silencing of X11γ enhanced endosomal/lysosomal sorting of APP and increased Aβ secretion.

Mammalian disabled (mDAB)-1 likewise interacts with both APP and ApoER2, and decreased both CTFβ and secreted Aβ in a reelin-dependent manner. Interestingly, X11α and mDab-1 exert opposing effects on APP processing, and when both proteins are co-expressed, the effect of X11α overrides that of mDab-1. Fe65 is involved in APP signaling through the AICD as well as several aspects of APP-processing, and it also binds ApoER2. The JIPs are scaffold proteins that could link APP to JNK associated apoptotic functions and kinesin that mediate APP (as well as ApoER2) axonal transport. The interactions between APP and these binding proteins, and the resulting influences on APP trafficking and processing are exceedingly complex, and the links between APP and ApoER2 pertaining to AD pathology needs further clarification.

ApoER2 belongs to the family of LDL receptor-related (LRP) proteins, several of which have been implicated in APP processing and AD. LRP1, a neuronal receptor for ApoE, binds to APP (either directly or through Fe65) affects Aβ generation and clearance in the brain. APP processing is mediated by LRP1 on multiple levels. Enhanced APP internalization through LRP expression decreased cell surface APP levels, thereby reducing APP-shedding and enhanced Aβ secretion. In a recent report, LRP1 expression was shown to regulate ApoE and cholesterol levels within the CNS. Interestingly, deletion of APP, APLP2, or components of the γ-secretase complex, enhanced the expression and function of LRP1 in a way that is reversible by forced overexpression of AICD. The latter, together with Fe65 and Tip60, interacts with the LRP1 promoter and suppresses its transcription. The cellular interaction between APP and LRP1 thus goes beyond the physical interactions during protein trafficking, but occurs at the level of gene transcription as well. Several genetic polymorphisms of LRP1 have indeed been weakly associated with AD.
On the other hand, LRP1B, a homologue of LRP1, appears to retain APP at the cell surface and reduced Aβ production due to its slower rate of endocytosis.\textsuperscript{141} Clearly, a detail understanding of LRP1 and LRP1B expression in AD-affected brain regions would be important, and may need to novel therapeutic approaches.

The neuronal sorting protein receptor-related containing LDLR class A repeats (SorLA) (also named SorL1 or LR11), is another neuronal sorting protein that plays pivotal roles in APP processing. SorLA has received much recent attention as a clear demonstration of genetic linkage of its variants to late-onset, sporadic AD has now been made,\textsuperscript{60} consistent with earlier findings that its expression is reduced in brains of sporadic AD but not in familial AD cases.\textsuperscript{142} SorLA interacts with both APP and BACE1, and its interaction with APP apparently reduced the latter’s interaction with BACE1.\textsuperscript{143} Overexpression of sorLA in neurons redistribution surface APP to the Golgi and decreased its processing to Aβ, whereas ablation of sorLA expression in knockout mice results in increased levels of Aβ in the brain.\textsuperscript{143-145} SorLA may act to retain APP in TGN, and its sorting activity is dependent on functional interaction with adaptor proteins involved in protein transport to and from the trans-Golgi network, such as GGA and phosphoprotein acidic cluster sorting protein-1 (PACS-1).\textsuperscript{146} SorLA is indeed an interesting and promising target for modulating \(\gamma\)-secretase activity, TMP21 may therefore have a separate modulation effect on APP traffic.

All the findings discussed above provide a general picture of how modulation of trafficking of APP and its secretases by various cellular factors could modulate Aβ generation. Broadly speaking, enhanced retrograde transport of APP out of the endosome to the TGN reduces Aβ production. Enhanced APP routing to, or reduction of its internalization from the cell surface, facilitates its non-amyloidogenic, \(\alpha\)-secretase-mediated processing. Changes in post-Golgi membrane trafficking in aging neurons that may influence APP processing may therefore precipitate late-onset, idiopathic AD.

**Axonal Transport and Alzheimer Disease**

Efficient and tightly regulated axonal transport from and to the neuronal cell body is essential for neuronal survival and function. Bidirectional transport of vesicles, organelles, cargo carriers and protein complexes occurs along specifically polarized microtubule tracks by engaging microtubule-dependent motor proteins of the kinesin and dynein superfamilies.\textsuperscript{154} Impair axonal transport as a result of gene mutations is known to predispose individuals to pathogenesis of several neurodegenerative diseases.\textsuperscript{155,156} Perhaps the most prominent of these are CNS motor neuron diseases such as amyotrophic lateral sclerosis (ALS).\textsuperscript{157} Mutation in the dynactin subunit, p150\textsubscript{Glued}, for example, is a genetic risk factor for ALS.\textsuperscript{158} In Huntington’s disease, the mutant huntingtin protein has an expanded polyglutamine tract and impairs axonal trafficking in mammalian neurons in vivo and in vitro.\textsuperscript{159} Certain forms of the peripheral neuropathy Charcot-Marie-Tooth type II could also result from mutations in traffic components such as the microtubule motor KIF1B,\textsuperscript{160} regulator of vesicular traffic such as Rab7,\textsuperscript{161} and neurofilament,\textsuperscript{162} that cause defects in axonal transport. There are many histopathological as well as cellular and molecular links between AD and defects in axonal transport, as elaborated in more detail below.

**Impairment of axonal transport in AD.** The two major pathological hallmark features of AD are amyloid plaques consisting of aggregated Aβ and neurofibrillary tangles (NFT) containing hyperphosphorylated tau. Another prominent histopathological manifestation of AD is the presence of abnormal and dystrophic axons and dendrites. These may be associated with amyloid plaques and NFTs,\textsuperscript{163,164} but are in some cases found unassociated with either plaques or tangles.\textsuperscript{165,166} Mouse models overexpressing wild type and mutant forms of AD-related proteins such as APP,\textsuperscript{167} BACE1,\textsuperscript{168} PS1,\textsuperscript{169,170} tau,\textsuperscript{171,172} and ApoE4,\textsuperscript{173} have all been shown to exhibit axonal defects as in human AD. Interestingly, co-expression of the Drosophila homologue of APP, ApPli, together with tau, also disrupts axonal transport in flies.\textsuperscript{174} Selective white matter changes indicative of axonopathy are readily detected by magnetic resonance imaging (MRI) of AD patients.\textsuperscript{175,176} All the above indicate that AD pathogenesis causes axonal defects. That dystrophic axons could be found before clear plaque deposition or tangle formation in transgenic animals, and that white matter changes could be detected in pre-AD patients, would also suggest that axonal defects occurs rather early in AD pathogenesis.

How exactly does onset of AD pathology result in axonal defects? It is worth noting that many proteins associated with the pathogenesis of AD are transported to the axons and the presynaptic...
compartment,\textsuperscript{177,178} and that synaptic release of Aβ contributes significantly to extracellular amyloid deposits.\textsuperscript{179} APP has been shown to undergo fast axonal transport\textsuperscript{108} through direct binding with kinesin-1.\textsuperscript{180} It was in fact suggested that BACE1 and PS-1 are also co-transported with APP in a membranous vesicular compartment, with the latter functioning like a membrane receptor for kinesin-1.\textsuperscript{181} These earlier findings have recently been disputed,\textsuperscript{182} but there is little doubt that axonal/ presynaptic trafficking of APP and its processing enzymes occurs in normal and dystrophic neurons. Another point to note is that APP (and BACE1 and PS-1) are often found to accumulate in damaged axons following traumatic brain injury,\textsuperscript{183,184} probably resulting from axolemmal disruption and impaired axonal transport.\textsuperscript{185} Traumatic brain injury is a known epigenetic risk factor for AD,\textsuperscript{186} and one plausible link could be aberrant production of neurotoxic Aβ with a detrimental positive feedback mechanism that further damages the surviving axons.

In understanding the basis of axonal transport defects in AD, a particularly relevant point to consider is the involvement of abnormally phosphorylated tau in AD pathology. Tau is an axonally transported microtubule-associated protein.\textsuperscript{187} Hyperphosphorylation of tau not only results in a loss of function in terms of impaired microtubule binding, but probably also a toxic gain of function\textsuperscript{188} that may disrupt axonal transport.\textsuperscript{189,190} Tau is known to be involved in regulating axonal transport, and this notion is augmented by recent evidence showing that tau interacts with the dynactin complex.\textsuperscript{191} Interestingly, in spite of the frequent presence of tau-associated NFTs in AD, no tau mutations have been identified for familial cases of AD.

The ontogenic relationships between amyloid plaques and NFTs have been enigmatic. Aβ may interact with tau, either directly or indirectly, resulting in the latter’s hyperphosphorylation\textsuperscript{192,193} and drives NFT formation.\textsuperscript{8,194} Aβ may also induce proteosomal impairments that affect tau degradation, leading to its accumulation.\textsuperscript{195} Aberrant activation of the tau-phosphorylating cyclin-dependent kinase 5 (Cdk5) has also been heavily implicated in AD pathogenesis.\textsuperscript{196} Aβ and other neuronal stress factors could activate calpain, thereby enhancing Cdk5 activation. Conversely, the neuroprotective sAPPα generated by the non-amyloidogenic processing of APP, suppresses Cdk5 activation. Recent advances also suggest that activated p25/ Cdk5 could induce the production and intraneuronal accumulation of Aβ in vivo, prior to any apparent tau or amyloid-associated neuro-pathology.\textsuperscript{197} Aberrant Cdk5 activation could therefore lie upstream of amyloidogenic Aβ production, with the latter feeding forward to further activate Cdk5, as well as glycogen synthase kinase 3-β (GSK-3-β), resulting in tau hyperphosphorylation at later stages.

**Could aging and brain injury-related axonal transport defects play a causal role in AD pathogenesis?** While it is clear that axonal defect is a key disease manifestation of AD and is responsible for its symptoms, could it also play a causal role in precipitating idiopathic AD? Available data indicate that axonal defects can be found in both pre-AD and AD brains, either in association or not in association with amyloid pathology. The latter, in particular, points to the possibility that axonal defects could coincide with the earliest stages of AD pathogenesis. Particularly strong evidence for axonal defects underlying AD pathogenesis has been presented by Goldstein and colleagues.\textsuperscript{167} The authors showed that reducing kinesin-1 gene dosage by half in APP transgenic mice enhanced axonal defects, Aβ generation and amyloid deposition. The latter likely resulted from increased APP amyloidogenic processing in transport retarded axons.\textsuperscript{198}

Idiopathic, late-onset AD is an age-dependent disease, and is therefore expected to be influenced and precipitated by chronic cellular defects that accumulate as the individual ages. An example of such contributive factors to AD that has received popular attention is oxidative stress and related mitochondrial dysfunction.\textsuperscript{199} The potential of cumulative focal blockages in axonal transport resulting from a myriad of factors such as physical trauma and neurochemical toxicity in initiating AD pathogenesis are difficult to assess, but are definitely plausible. Injury to axons causes the formation of axonal spheroids—focal swellings that likely result from block transport.\textsuperscript{200} Speculatively, what could possibly happen is that the accumulation of stalled APP and its processing enzymes in these focal injuries, resulting in increased APP processing and Aβ generations, perhaps even in a way that favors amyloidogenic ratios of Aβ40/Aβ42. These, together with other factors associated with brain injury (such as neuroinflammation), triggers a cascade of events that might increase tau phosphorylation and NFT formation. The notion of chronic and cumulative axonal transport defects leading to AD pathogenesis is attractive, and is an avenue for potential therapeutic interventions. However, further understanding of the underlying processes involved in the transition from axonal defect to AD is needed.

**Aβ-induced Synaptic Defects and Glutamate Receptor Trafficking**

Dementia, which is generally preceded by memory deficits and a decline in cognitive functions, is the primary neurological defect associated with AD. The amyloid cascade hypothesis as it was originally proposed suggests that accumulation of fibrillar β-amyloid and their deposition as insoluble extracellular plaques underlies these neurological deficits. A major caveat for the above notion is that amyloid burden does not necessarily correlate well with clinical severity of AD. In some cases AD symptoms and neuronal loss could be traced to brain regions that are amyloid free. Furthermore, memory and cognitive function deficits could become obvious much earlier than plaques. An opposite notion in fact suggests that the insoluble amyloid deposits are sinks, rather than sources of Aβ toxicity. Recent findings have indicated that non-fibrillar, soluble oligomers of Aβ could cause cognitive deficits by impairing synaptic function.\textsuperscript{12,13} Aβ oligomers could induce aberrations in synapse composition, shape and density, particularly in AD relevant excitatory pyramidal neurons.\textsuperscript{201,202} Aβ oligomers may act presynaptically, suppressing spontaneous synaptic activity by inhibition of P/Q-type calcium currents,\textsuperscript{203} or by disrupting synaptic vesicle endocytosis.\textsuperscript{204} Soluble Aβ interacts with several receptor molecules, and have been postulated to disrupt synaptic memory mechanisms via stress-activated kinases and mediators of oxidative stress.\textsuperscript{205} Excitatory transmissions could be depressed by both presynaptic and postsynaptic mechanisms.\textsuperscript{206} A particularly relevant aspect Aβ’s effect on synapses in AD is the impairment of hippocampal LTP.\textsuperscript{207} It has in fact been shown that neuronal activity could modulate the formation and secretion of Aβ in hippocampal slices, with the peptide in turn depressing excitatory synaptic transmission.\textsuperscript{208} An important underlying mechanism by which Aβ suppress LTP (and presumably induce consequential memory impairment),
appears to be its influence on synaptic AMPA and NMDA receptors. AMPA receptors are the major excitatory neurotransmitter receptors in the brain, and its expression levels at the synapses are highly dynamic. Regulation of AMPA receptor to and from the synaptic plasma membrane, and localized recycling of AMPA receptors at dendritic spines are major mechanism underlying synaptic plasticity. Aβ could interact directly with AMPA receptors and influence receptor function and channel activity, and this may occur to varying degrees depending on Aβ levels. A more eminent mechanism by which Aβ induces synaptic depression involves a dynamic loss of AMPA receptor from dendritic spine surfaces via endocytosis. Interestingly, this is mediated by signaling pathways similar to that occurring during LTD, involving calcineurin and p38 MAP kinase.

Aβ-induced depression of excitatory transmission and synaptic spine loss is dependent on NMDA receptor activity. Although not perceived to be as dynamic as AMPA receptor, activity modulated alterations in NMDA receptor trafficking contributes to homeostatic plasticity. Intriguingly, Aβ also promotes the endocytosis of NMDA receptors, and does this via binding to α7 nicotinic acetylcholine receptor, initiating subsequent signaling processes that require calcineurin and the tyrosine phosphatase STEP (streiatal-enriched phosphatase). Although Aβ’s direct binding to α7 nicotinic acetylcholine receptor is a controversial issue, Aβ treatment reduced surface NR2B and NR1, but not GABA receptor subunits.

Concluding Remarks

Advances in our basic understanding of biology are sometimes driven by intense efforts galvanized by the need to resolve a clinical problem. AD exemplifies such cases, as it is an exceptionally fascinating disease in terms of molecular and cellular etiology. Much of our understanding of the importance and mechanism of intramembrane proteolysis, for example, could be attributed to investigations on APP processing. In a similar way, studies on the subcellular trafficking and dynamics of the membrane proteins associated with AD pathology are also pushing the frontiers of our understanding of protein trafficking in neurons. Much is now known, but there is much more to be learned. A detailed understanding of factors that influence neuronal trafficking processes will open up novel therapeutic avenues for AD, as well as other neurodegenerative disorders.

Acknowledgements

The author declares no financial conflict of interest. The exceptionally vast relevant literature had prevented direct citation of many excellent works, and I apologize for this glaring inaccuracy in this short overview.

References

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Alzheimer’s Disease International. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366:214-7.
2. Goedert M, Ghetti B. Alois Alzheimer: his life and times. Brain Pathol 2007; 17:57-62.
3. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006; 314:777-81.
4. Hardy J. A hundred years of Alzheimer’s disease research. Neuron 2006; 52:3-13.
5. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochem Biophys Acta 2005; 1739:198-210.
6. Glerum GC, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885-90.
7. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald B, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82:4245-9.
8. Blum-Brown-Mc and Lefler FM. Pathways by which Aβ facilitates tau pathology. Curr Alzheimer Res 2006; 3:437-48.
9. King ME, Kan HM, Baas PW, Eröz A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid. J Cell Biol 2006; 175:541-6.
10. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002; 297:353-6.
11. Lee HG, Casadeu G, Zhu X, Joseph JA, Perry G, Smith MA. Perspectives on the amyloid-β cascade hypothesis. J Alzheimers Dis 2004; 6:137-45.
12. Lesne S, Koh MT, Kortlink L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006; 440:352-7.
13. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuszkowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 2005; 8:79-84.
14. Hoosenns JJ, Chafekar SM, Baas F, Eekelenboom P, Scheper W. Always away, never around: the same pathway of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer’s disease. Curr Med Chem 2006; 13:2599-605.
15. Wirths O, Multhaup G, Bayer TA. A modified β-amyloid hypothesis: intracellular accumulation of the β-amyloid peptide—the first step of a fatal cascade. J Neurochem 2004; 91:513-20.
16. Cuollo AC. Intracellular and extracellular Aβ, a tale of two neuropathologies. Brain Pathol 2005; 15:66-71.
17. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci 2007; 8:499-509.
18. Haass C. Take five—BACE1 and the γ-secretase quartet. Curr Alzheimer Res 2004; 1:205-11.
19. Wilkues V, De Strooper B. Amyloid-β precursor protein processing in neurodegeneration. Curr Opin Neurobiol 2004; 14:582-8.
20. Vassar R, Bennett BD, Babu-Khan S, Kuhl S, Mendia E, Denis P, et al. Beta-secretase cleavage of Alzheimer’s amyloid β-protein precursor by the transmembrane aspartic protease BACE1. Science 1999; 286:735-41.
21. Vassar R. BACE1: the β-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2004; 2:105-14.
22. Zhang Y, McLaughlin R, Goodyear C, LeBlanc A. Selective cytotoxicity of intracellular amyloid-β peptide 1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002; 156:519-29.
23. Kim W, Hecht MH. Sequence determinants of enhanced amyloidogenicity of Alzheimer AP42 peptide relative to AP40. J Biol Chem 2005; 280:35069-76.
24. Awantl A, Matsunaga Y, Yamada T. Amyloid-β causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-β-derived short peptides. Exp Neurol 2005; 196:282-9.
25. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, et al. Amyloid β-protein (Aβ1-40) protects neurons from damage induced by Aβ1-42 in culture and in the brain. J Neurochem 2003; 87:609-19.
26. Yan Y, Wang C. AP40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 2007; 369:909-16.
27. Allenson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein γ-secretase. J Neurosci Res 2003; 74:342-52.
28. Mattson MP. Secreted forms of β-amyloid precursor protein modulate dendritic outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol 1994; 25:439-50.
29. Meiziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, et al. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998; 95:12683-8.
30. Tang BL. Alzheimer’s disease: channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun 2005; 331:375-8.
31. Fahrenholz F, Postina R. Alpha-secretase activation—an approach to Alzheimer’s disease therapy. Neurodegener Dis 2006; 3:255-61.
32. Kopan R, Fagan MM. Gamma-secretase: protease of the membrane? Annu Rev Neurosci 2004; 27:105-14.
33. Romano ML, Meroz V, Axelsen P, Klaholz B, Selkoe DJ. BACE1: the β-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2004; 2:105-14.
34. Patel S, Zhang Y, McLaughlin R, Goodyear C, LeBlanc A. Amyloid β-protein (Aβ1-40) protects neurons from damage induced by Aβ1-42 in culture and in the brain. J Neurochem 2003; 87:609-19.
35. Yan Y, Wang C. AP40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 2007; 369:909-16.
36. Allenson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein γ-secretase. J Neurosci Res 2003; 74:342-52.
37. Mattson MP. Secreted forms of β-amyloid precursor protein modulate dendritic outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol 1994; 25:439-50.
38. Meiziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, et al. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998; 95:12683-8.
39. Tang BL. Alzheimer’s disease: channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun 2005; 331:375-8.
40. Fahrenholz F, Postina R. Alpha-secretase activation—an approach to Alzheimer’s disease therapy. Neurodegener Dis 2006; 3:255-61.
41. Kopan R, Fagan MM. Gamma-secretase: protease of the membrane? Annu Rev Neurosci 2004; 27:105-14.
42. Romano ML, Meroz V, Axelsen P, Klaholz B, Selkoe DJ. BACE1: the β-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2004; 2:105-14.
Neuronal trafficking associated with Alzheimer disease

39. Edbauer D, Winkler E, Regala JT, Pesold B, Steiner H, Haass C. Reconstitution of γ-secretase activity. Nat Cell Biol 2003; 5:486-8.

40. Chen F, Hasegawa H, Schmitt-Ulms G, Kowari T, Bohn C, Katayama T, et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 2006; 440:1208-12.

41. Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcellular trafficking. J Biol Chem 2004; 279:24601-11.

42. Von Rors RC, Kohli BM, Bosser J, Meier M, Suzuki T, Nitsch RM. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own promoter. J Cell Sci 2007; 117:4435-48.

43. Galvan V, Chen S, Lu D, Logovina A, Goldsmith P, Koo EH, et al. Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem 2002; 82:283-94.

44. Lu DC, Soriano S, Bredesen DE, Koo EH. Caspase cleavage of the amyloid precursor protein modules amyloid-β protein toxicity. J Neurochem 2003; 87:73-41.

45. Park JH, Kim SS, Song YM, Kim HH, Goo HG, Yoon EJ, et al. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J Biol Chem 2006; 281:34277-87.

46. Tanai RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120:545-55.

47. Ertekin-Taner N. Genetics of Alzheimer’s disease: a centennial review. Neurol Clin 2007; 25:611-67.

48. Kowalska A. Amyloid precursor gene function mutations responsible for early-onset autosomal dominant Alzheimer’s disease. Folia Neuropathol 2003; 4:35-40.

49. Czech C, Trimp G, Pradier L. Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms. Prog Neurobiol 2006; 86:363-8.

50. Duft K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383:710-3.

51. Citron M, Westaway D, Xia W, Carlon G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid-beta protein in both transfected cells and transgenic mice. Nat Med 1997; 3:67-72.

52. Huang Y, Weigauer KJ, Mucke L, Mäley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. J Mol Neurosci 2004; 23:189-204.

53. Poitier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer’s disease. Neurobiol Aging 2005; 26:555-61.

54. Sambamurti K, Granholm AC, Kindy MS, Bhar NR, Geer NH, Lahiri DK, et al. Cholesterol and Alzheimer’s disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 2004; 5:517-28.

55. Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer’s disease-related with increased amyloid-β expression alters the subcellular processing of amyloid precursor protein and inhibits Aβ production. J Biol Chem 2004; 279:18851-6.

56. Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, et al. Rabs5-stimulated upregulation of the endocytic pathway increases intracellular β-cleared amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J Biol Chem 2005; 278:31261-8.

57. Corsetti RM, Balca BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytic activity increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid β protein. BMC Cell Biol 2005; 6:30.

58. Hsu JT, Pijack DS, Leslie GJ, Lee VY, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme, the Alzheimer’s disease β-secretase. J Biol Chem 2000; 275:33729-37.

59. Kinoshita A, Fukushima H, Shuk T, Whelan CM, Itirassy MC, Hyman BT. Demonstration by FRET of BACE1 interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 2003; 116:3339-46.

60. Ermolieff J, Loy JA, Koelsch G, Tang J. Proteolytic activation of recombinant pro-memapsin-2 (pro-β-secretase) studied with new fluorogenic substrates. Biochemistry 2000; 39:12450-6.

61. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994; 269:17386-9.

62. Tate BA, Mathews PM. Targeting the role of the endosome in the pathophysiology of Alzheimer’s disease: a strategy for treatment. Sci Aging Knowledge Environ 2006; 2006:2.

63. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, et al. Muratogenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ42. J Biol Chem 1999; 274:18851-6.

64. Barme S, Frohman M, Zhong M, Lin Y, Du G, Frohman L, et al. Presenilin-1 uses phospholipase D1 as a negative regulator of cell surface delivery of the presenilin-1. Neuron 1998; 19:469-84.

65. Li R, Lindholm K, Yang I, Yue X, Citron M, Yang R, et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA 2004; 101:3632-7.

66. Sjogren M, Mielke M, Gustafson D, Skoog I. Cholesterol and Alzheimer disease-related with increased amyloid-β expression. J Neurosci 2004; 24:1237-44.
Neuronal protein trafficking associated with Alzheimer disease

100. Zhang M, Haapasalo A, Kim DY, Ingano LA, Perringill WH, Kwacs DM. Presenilin-1/β-secretase activity regulates protein clearance from the endocytic recycling compartment. J Biol Chem 2006; 281:27778-88.

101. Rossner S, Apelt J, Schild R, Perez-Polo JR, Bigl V. Neuronal and glial β-secretase (BACE1) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 2001; 64:437-46.

102. Tang BL. Emerging aspects of membrane traffic in neuronal dendrite growth. Biochem Biophys Acta 2008 1783:169-76.

103. Dugan JM, DeWit C, McConlogue L, Maltese WA. Differential effects of a GTPase-activating protein on EGFR trafficking. J Biol Chem 1995; 270:10982-9.

104. Riemenschneider M, Schoepfer-Wendels A, Friedrich P, Konta L, Laws SM, Mueller JC, et al. No association of vacuolar protein sorting 26 polymorphisms with Alzheimer's disease. Biophys Acta 2008 1783:169-76.

105. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent β-secretase competence is enhanced by SorLA/LR11-dependent trafficking of amyloid precursor protein by the trans-Golgi network. J Biol Chem 2000; 275:2568-75.

106. Faundez V, Fang G, Rees H, Rebeck GW. DAB1 and Reelin effects on amyloid precursor protein and Aβo: receptor 2 trafficking and processing. J Biol Chem 2006; 281:35176-85.

107. Liu Q, Zerbinatti CV, Zhang J, Ho E, Wang B, Cole SL, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neurobiol Aging 2007; 28:22946-55.

108. He X, Cooley J, Chung CH, Dashti N, Tang J. Apolipoprotein receptor 2 and X11

109. Lee VM. Protein kinase C-dependent β-secretase competence is enhanced by SorLA/LR11-dependent trafficking of amyloid precursor protein by the trans-Golgi network. J Biol Chem 2000; 275:2568-75.

110. Capell A, Meyn L, Fluhser R, Teplow DB, Walter J, Haas C. Apical sorting of β-secretase limits amyloid β-peptide production. J Biol Chem 2002; 277:5637-43.

111. Kawasumi M, Matsuda S, Matsuoka M, Nishimoto I. Cytoplasmic tail adaptors of Alzheimer's amyloid protein. J Biol Chem 1995; 270:10982-9.

112. McConlogue L, Castellano F, DeWit C, Schenk D, Maltese WA. Differential effects of a GTPase-activating protein on EGFR trafficking. J Biol Chem 1995; 270:10982-9.

113. Dugan JM, DeWit C, McConlogue L, Maltese WA. The Ras-related GTP-binding protein, Rab18, regulates early steps in endocytic transport and processing of β-amyloid precursor protein. J Biol Chem 1995; 270:10982-9.

114. Spoelgen R, Von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, et al. Interaction of the cytosolic domains of solf/LR11 with the amyloid precursor protein (APP) and β-secretase-siite APP-degrading enzyme. J Neurosci 2006; 26:418-28.

115. Bonifacino JS. The GGA proteins: adaptors on the move. Nat Rev Mol Cell Biol 2004; 5:23-32.

116. Liu Q, Zerbinatti CV, Zhang J, Ho E, Wang B, Cole SL, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neurobiol Aging 2007; 28:22946-55.

117. Simons M, Ikonen E, Tienari PJ, Cid-Arregui A, Mönning U, Beyreuther K, et al. Precursor protein. J Biol Chem 1991; 266:18219-23.

118. Medin SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, et al. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol 2005; 58:646-70.

119. Andersen OM, Reiche J, Schmidt V, Sporbert A, Rohe M, Rehm A, Andersen OM, et al. SorLA/LR11 regulates amyloid β-secretase beta-site APP-cleaving enzyme. J Neurosci 2006; 26:418-28.

120. Back S, Haas P, Tschäpe JA, Gruebl T, Kirsch J, Müller U, et al. Neuronal protein trafficking associated with Alzheimer disease

121. Cam JA, Bu G. Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 2006; 18:1-8.

122. Schliebs R, Perez-Polo JR, Bigl V. Neuronal and glial β-secretase activity regulates the transport of the Alzheimer's amyloid precursor protein by a disintegrin metalloproteinase. Proc Natl Acad Sci USA 1999; 96:3922-7.

123. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. ADP-ribosylation factor-dependent adaptor that regulates the traffic of the Alzheimer's disease-associated presenilin 1. Proc Natl Acad Sci USA 1990; 87:1561-5.

124. Horiuchi D, Collins CA, Bhat P, Barkus RV, Diantonio A, Saxton WM. Control of a neuronal protein trafficking associated with Alzheimer disease

125. McConlogue L, Castellano F, DeWit C, Schenk D, Maltese WA. Differential effects of a GTPase-activating protein on EGFR trafficking. J Biol Chem 1995; 270:10982-9.

126. Andersen OM, Reiche J, Schmidt V, Sporbert A, Rohe M, et al. Neuronal sorting protein-receptor receptor solf/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2005; 102:13461-6.

127. Simon M, Ikonen E, Tienari PJ, Cid-Arregui A, Mönning U, Beyreuther K, et al. Intracellular routing of human amyloid protein precursor: axonal delivery followed by transport to the dendrites. J Neurosci Res 1995; 41:121-8.

128. Simons M, Ikonen E, Tienari PJ, Cid-Arregui A, Mönning U, Beyreuther K, et al. Intracellular routing of human amyloid protein precursor: axonal delivery followed by transport to the dendrites. J Neurosci Res 1995; 41:121-8.

129. McConlogue L, Castellano F, DeWit C, Schenk D, Maltese WA. Differential effects of a Rab6 mutant on secretory and endocytic protein trafficking in cultured neurons. J Cell Biol 2003; 162:623-8.

130. Palaisidou I, Efthimiopoulos S. Expression of mdab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11. Neuron Aging 2007; 28:377-88.

131. McConlogue L, Castellano F, DeWit C, Schenk D, Maltese WA. Differential effects of a GTPase-activating protein on EGFR trafficking. J Biol Chem 1995; 270:10982-9.

132. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, et al. Precursor protein. J Biol Chem 1991; 266:18219-23.

133. Dugan JM, DeWit C, McConlogue L, Maltese WA. The Ras-related GTP-binding protein, Rab18, regulates early steps in endocytic transport and processing of β-amyloid precursor protein. J Biol Chem 1995; 270:10982-9.

134. Matsuda S, Yasukawa T, Hayakawa A, Takata H, Suzuki T, Miyazawa K, et al. A scaffold protein. J Biol Chem 2007; 282:33313-25.

135. Matsuda S, Yasukawa T, Hayakawa A, Takata H, Suzuki T, Miyazawa K, et al. A scaffold protein. J Biol Chem 2007; 282:33313-25.

136. Horiuchi D, Collins CA, Bhat P, Barkus RV, Diantonio A, Saxton WM. Control of a neuronal protein trafficking associated with Alzheimer disease

137. McConlogue L, Castellano F, DeWit C, Schenk D, Maltese WA. Differential effects of a GTPase-activating protein on EGFR trafficking. J Biol Chem 1995; 270:10982-9.

138. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent β-secretase competence is enhanced by SorLA/LR11-dependent trafficking of amyloid precursor protein by the trans-Golgi network. J Biol Chem 2000; 275:2568-75.

139. Faundez V, Fang G, Rees H, Rebeck GW. DAB1 and Reelin effects on amyloid precursor protein and Aβo: receptor 2 trafficking and processing. J Biol Chem 2006; 281:35176-85.
Neuronal protein trafficking associated with Alzheimer disease

160. Zhao C, Takita J, Tanaka Y, Senou M, Nakagawa T, Takeda S, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bβ. Cell 2001; 105:587-97.
161. Megahed F, Bienfait HM, Weereman DF, De Visser M, Baas F. Charcot-Marie-Tooth disease type 2A due to a de novo mutation of the RAB7 gene. Neurology 2006; 67:1476-8.
162. Brownless J, Ackerley S, Grieron AJ, Jacobsen NJ, Shea K, Anderton BH, et al. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet 2002; 11:2837-44.
163. Dickson TC, Vickers JC. The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience 2001; 109:99-107.
164. Spires TL, Hyman BT. Neuronal structure is altered by amyloid plaques. Rev Neurosci 2004; 15:267-78.
165. Munoz DG, Wang D. Tangle-associated neuritic clusters. A new lesion in Alzheimer's disease due to a de novo mutation of the RAB7 gene. Neurology 2002; 59:522-7.
166. Stamer K, Voger R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002; 156:1051-63.
167. Mandelkow EM, Stamer K, Voger R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24:1079-85.
168. Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, et al. Interaction of tau protein with the dynactin complex. EMBO J 2004; 23:4564-56.
169. Zheng WH, Bartainetto S, Mannenick F, Ma W, Kar S. Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002; 115:201-11.
170. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 2008; 29:1334-47.
171. Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein and neurodegeneration in Alzheimer’s disease. Neurobiol Mol Med 2002; 2:2151-65.
172. Oddo S, Billings L, Keslak JP, Chrisib DH, Laferla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuro 2004; 43:321-32.
173. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer’s disease. Trends Mol Med 2004; 10:452-8.
174. Cruz JC, Kim D, Mey L, Dubbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J Neurosci 2006; 26:10536-41.
175. Stokin GB, Goldstein IS. Axonal transport and Alzheimer's disease. Annu Rev Biochem 2006; 75:607-27.
176. Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Kreid U, Srozmenaj BD, et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease? Antioxid Redox Signal 2007; 9:1659-75.
177. Coleman M. Axon degeneration mechanisms: Commonality amid diversity. Nat Rev Neurosci 2005; 6:889-99.
178. Lacor PN, Buncl M, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Aβ oligomer-induced aberrations in synapse composition, shape and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 2007; 27:7956-70.
179. Fujii A, Prince RW, Velasco PT. Aβ oligomer-induced microtubule and synapse loss in hippocampal neurons: two lesions in Alzheimer’s disease. Neurobiol Aging 2008; 29:1334-47.
180. Kelly BL, Ferreira A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience 2007; 147:60-70.
181. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer’s disease amyloid β-peptide-induced dysfunction. Biochem Soc Trans 2007; 35:1129-23.
182. Ting JT, Kellog B, Lambert TJ, Cook DG, Sullivan JM. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci USA 2007; 104:353-8.
183. Chen QG, Kagan BL, Hirakawa Y, Xie CW. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2006; 80:65-72.
184. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vitro. Nature 2002; 416:535-9.
185. Shepherd JD, Flugan RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 2007; 23:613-43.
186. Goger IH, Esterban JA. AMPA receptor biogenesis and trafficking. Curr Opin Neurobiol 2007; 17:289-49.
187. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117:5271-9.
188. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117:5271-9.
189. Walker J, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP Nature 2004; 414:643-8.
190. Laras A, Moefini GA, Lee EB, Farah MH, Sozdoria A, et al. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revised. J Neurosci 2005; 25:2386-95.
191. Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following traumatic brain injury. J Neurochem 2004; 89:357-71.
192. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DJ, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 2007; 208:185-92.
193. Stone JR, Okonkwo DO, Dialo AO, Rubin DG, Mutlu LK, Powlishock JT, et al. Impaired axonal transport and altered axonal permeability occur in distinct populations of damaged axons following traumatic brain injury. Exp Neurol 2004; 190:59-69.
194. Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McNinch TK. Protein accumulation in traumatic brain injury. Neurochem Mol Med 2003; 4:59-72.
195. Urtom JA, Noble WJ, Hill JE, Anderton BH, Hanger DP. Molecular motors implicated in the axonal transport of tau and ε-synuclein. J Cell Sci 2005; 118:4635-45.